KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $53.1 million.

  • AbCellera Biologics' Other Non-Current Assets fell 6046.19% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 6046.19%. This contributed to the annual value of $96.5 million for FY2024, which is 243.41% up from last year.
  • AbCellera Biologics' Other Non-Current Assets amounted to $53.1 million in Q3 2025, which was down 6046.19% from $57.5 million recorded in Q2 2025.
  • AbCellera Biologics' Other Non-Current Assets' 5-year high stood at $134.2 million during Q3 2024, with a 5-year trough of $9.5 million in Q1 2021.
  • Its 5-year average for Other Non-Current Assets is $66.8 million, with a median of $57.5 million in 2025.
  • In the last 5 years, AbCellera Biologics' Other Non-Current Assets surged by 35443.02% in 2022 and then crashed by 6046.19% in 2025.
  • AbCellera Biologics' Other Non-Current Assets (Quarter) stood at $30.6 million in 2021, then soared by 51.2% to $46.3 million in 2022, then surged by 103.41% to $94.2 million in 2023, then increased by 2.43% to $96.5 million in 2024, then tumbled by 45.03% to $53.1 million in 2025.
  • Its Other Non-Current Assets was $53.1 million in Q3 2025, compared to $57.5 million in Q2 2025 and $61.6 million in Q1 2025.